6-Oct-2008

ASX RELEASE

‘Know Your L-Dex™’ (Lymphedema Index) Awareness Campaign Set for Kick-Off in National Breast Cancer Awareness Month

ImpediMed Limited attach for the information of shareholders a press release issued in the US late Friday Australian time regarding a campaign launched at a Breast Cancer awareness event in Houston Texas on Saturday Oct 4th 2008.

The release covers the launch of what is expected to be a significant awareness campaign on the company’s L-Dex™ readings generated by the Lymphoedema product range. L-Dex™ is a trademark of ImpediMed Limited.

For more information contact:

Greg Brown Chief Executive Officer +61-7-3860-3700

www.impedimed.com
FOR IMMEDIATE RELEASE

Media Contacts: Wendy Lau or Bianca Molina
Russo Partners
(212) 845-4272 office
(917) 412-3379 mobile
wendy.lau@russopartnersllc.com
bianca.molina@russopartnersllc.com

‘Know Your L-Dex™’ (Lymphedema Index) Awareness Campaign Set for Kick-Off in National Breast Cancer Awareness Month

Breast Surgeons to Conduct Complimentary L-Dex Readings, Discuss Benefits of Early Lymphedema Assessment, Treatment at Susan G. Komen for the Cure, Breast Cancer Network of Strength Events

SAN DIEGO, Oct. 2, 2008 – The first-ever “Know Your L-Dex” (Lymphedema Index) awareness campaign is set for kick-off this week as part of National Breast Cancer Awareness Month activities.

At Susan G. Komen for the Cure and Breast Cancer Network of Strength events throughout the United States, breast surgeons will provide female breast cancer survivors with complimentary L-Dex readings using an L-Dex XCA medical device – the first FDA cleared device of its type – developed by ImpediMed Ltd. The readings will serve as an aid for medical professionals to clinically assess, and monitor for the early signs of unilateral lymphedema of the arm (swelling that occurs in one arm following breast cancer treatment), potentially before symptoms such as heaviness or visible swelling are present.

In addition to performing the readings, the breast surgeons on hand will discuss the potential benefits of the early assessment and treatment of lymphedema, such as preventing the progression of the disorder to an irreversible condition that can affect an individual’s quality of life and appearance. Data from a five-year study recently published in the medical journal Cancer, using a standardized volumetric technique for the pre-operative assessment and early detection of lymphedema, demonstrated the importance of physicians pre-operatively assessing patients and conducting ongoing surveillance for the early detection and successful treatment of lymphedema. ImpediMed devices were not used in this study.

“Ask breast cancer patients what is one of their major concerns after treatment and you are likely to hear the development of lymphedema over and over again,” said Walton Taylor, M.D., a breast surgeon in Texas who will participate in the “Know Your L-Dex” events. “L-Dex measurements are quick, non-invasive, painless readings that enable medical professionals to clinically assess lymphedema at earlier stages and show how any treatment or management of the condition is working.”

The preliminary “Know Your L-Dex” campaign line-up includes activities at:

- Komen Houston Race for the Cure
  Oct. 4, Sam Houston Park Downtown, Houston

- Komen Dallas Race for the Cure
  Oct. 18, North Park Center, Dallas
About Lymphedema

Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body and is a key component of the immune system, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that 6 percent to 40 percent of patients with breast cancer develop lymphedema, and that it often occurs within the first two years after surgery. For some cancer survivors and others at risk, a low level lymphedema can occur 10 years to 15 years following the initial primary treatment and develop into a condition that has a serious impact on overall health and quality of life.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedence Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that enable surgeons, oncologists, therapists and radiation oncologists to clinically assess patients for the potential onset of secondary lymphedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphedema of the arm in female breast cancer patients. For more information, visit www.impedimed.com.

Note: ImpediMed’s device is not intended to diagnose or predict lymphedema of an extremity.